Clinical Application of Advances in Metastatic Prostate Cancer: Education and Resources for Nurses

Join us in-person or virtually for this live, 1-hour, CE-certified workshop series on the latest clinical advances in metastatic prostate cancer led by nurses, for nurses. Get up to date on the current treatment landscape and key nursing considerations in the castration-sensitive and castration-resistant settings, along with practical guidance on supportive care, patient adherence, financial toxicity, and managing adverse events.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the webinar.


  • Introduction
  • Case Discussion: Overview of the Current Treatment Landscape for mCSPC and Implications for Nursing Practice
  • Case Discussion: Overview of the Current Treatment Landscape for mCRPC and Nursing Considerations
  • Advances and Future Directions for Patients With Metastatic Prostate Cancer


Date / Time
Event Details


Program Director
Kathleen Burns, MSN, RN, AGACNP-BC, OCN®

Nurse Practitioner
GU Medical Oncology
City of Hope National Medical Center
Duarte, California

Program Director
Brenda Martone, MSN, ANP-BC, AOCNP

Nurse Practitioner
Department of GU Oncology
Northwestern Medicine
Chicago, Illinois

Mary Weinstein Dunn, MSN

Nurse Practitioner
Division of Oncology
Department of Urology
Department of Medicine
University of North Carolina Chapel Hill
Chapel Hill, North Carolina

Goal Statement
The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with prostate cancer.

Target Audience
This program is intended for oncology nurses and other HCPs who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss with patients the current evidence-based treatment and supportive care options available for metastatic castration-sensitive and castration-resistant prostate cancer
  • Effectively communicate to colleagues and patients the rationale for PARP inhibitor–based regimens in metastatic prostate cancer, in tumors with or without DNA damage repair alterations
  • Counsel patients on the administration and management of unique toxicities associated with targeted therapies
  • Develop a proactive management plan to support adherence in patients receiving oral therapies
  • Identify patients suitable for enrollment on ongoing clinical studies investigating combination regimens in metastatic prostate cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Designation of Credit

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.